Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

UCLA advances CRISPR gene-editing therapy for sickle cell disease (opens in a new tab)

news-medical.net · 2026-11-04

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportsmentioned without context

    Development of CRISPR_SCD001, an autologous hematopoietic stem cell gene therapy for sickle cell disease

    Molecular Therapy · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Development of crispr_scd001, an autologous hematopoietic stem cell gene therapy for sickle cell disease

    Where the story links (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 5Not checkedA UCLA-led team has advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial.View evidenceHide evidence

As statedclinical-trial scale

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 5Not checkedThe therapy uses CRISPR-Cas9 gene editing to correct the single-point mutation that causes sickle cell disease in a patient’s own blood-forming stem cells.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 5Not checkedIn preclinical studies, the researchers established a reproducible manufacturing process and showed that red blood cells differentiated in vitro from edited stem cells produced less sickle hemoglobin than those grown from unedited cells.View evidenceHide evidence

As statedless sickle hemoglobin

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 5Not checkedThe article says the proportion of corrected gene copies did not significantly decrease after the edited human cells were transplanted into mice and allowed to engraft for 16 weeks.View evidenceHide evidence

As stated16 weeks

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 5Not checkedThe manufacturing process has been implemented at UCLA to produce cell products for two trial participants in an ongoing phase 1 clinical trial led by Dr. Mark Walters at UCSF Benioff Children’s Hospital Oakland.View evidenceHide evidence

As statedtwo trial participants

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Development of CRISPR_SCD001, an autologous hematopoietic stem cell gene therapy for sickle cell disease

Molecular Therapy · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref · 29 candidate papers

Selected

Development of CRISPR_SCD001, an autologous hematopoietic stem cell gene therapy for sickle cell disease

Molecular Therapy · 2026 · Crossref

Source (opens in a new tab)
Candidate

Author response: Inference of germinal center evolutionary dynamics via simulation-based deep learning

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response for "Ecological interactions mediate evolutionary responses to temperature in microbial communities"

2026 · Crossref

Source (opens in a new tab)

And 23 more candidates considered.